Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/27/23
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 12/15/21
End: 01/31/25
Due: 01/31/26
Phase: N/A
Priority: Normal
Start: 12/08/23
End: 06/30/27
Due: 06/30/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors | NCT05718895 | Antengene Biologics Limited | user2@example.com | None | 2023-03-27 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | NCT04986865 | Antengene Biologics Limited | user2@example.com | None | 2021-12-15 | 2025-01-31 | 2026-01-31 | - | - | 2025-07-14 |
| A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | NCT06028373 | Antengene Biologics Limited | user2@example.com | None | 2023-12-08 | 2027-06-30 | 2028-06-30 | - | - | 2025-07-14 |